Lingmi Hou1, Maoshan Chen2, Minghao Wang3, Xiang Cui3, Yanchun Gao4, Tianyong Xing4, Jingdong Li5, Shishan Deng6, Jiani Hu7, Hongwei Yang8, Jun Jiang9. 1. Breast Disease Center, Southwest Hospital, The Third Military Medical University, Chongqing 40038, China; Department of Thyroid Breast Surgery, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China; Institute of Hepatobiliary Pancreatic-Intestinal Diseases, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China. 2. Department of Breast and Thyroid Surgery, Suining Central Hospital, Suining, Sichuan 629000, China. 3. Breast Disease Center, Southwest Hospital, The Third Military Medical University, Chongqing 40038, China. 4. Department of Thyroid Breast Surgery, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China. 5. Institute of Hepatobiliary Pancreatic-Intestinal Diseases, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China. 6. Department of Anatomy, The North Sichuan Medical College, Nanchong, Sichuan 637000, China. 7. Department of Radiology, Wayne State University, Detroit, MI 48331, USA. 8. Department of Breast and Thyroid Surgery, Suining Central Hospital, Suining, Sichuan 629000, China. Electronic address: snhongweiyang@126.com. 9. Breast Disease Center, Southwest Hospital, The Third Military Medical University, Chongqing 40038, China. Electronic address: southwestbreast@163.com.
Abstract
BACKGROUND: Ductal carcinoma in situ (DCIS) is a common type of non-invasive breast cancer and can sometimes progress into invasive breast cancer (IBC). Identification of the critical genes and biological processes specifically and/or commonly changed in DCIS or IBC can help us understand more about breast cancer development and provide more critical targets and signal transduction pathways for the diagnosis and treatments for breast cancer patients. AIM AND METHODS: We aimed to gain more understanding about the whole process of IBC development, especially in the early stage. Here we systematically analyzed an online breast cancer patient database to identify those significantly changed genes and biological processes in epithelium from normal stage to DCIS stage or from DCIS stage to IBC stage. RESULTS: 344 specific genes, such as FN1, AURKA and HSPA8, were found to be significantly changed (both upregulated and downregulated) in DCIS group in comparison with normal tissue group, which represents the gene profile changes in early stage of breast cancer development. Meanwhile, 304 specific genes were significantly changed (both upregulated and downregulated) in IBC group in comparison with normal tissue group, which represents the gene profile changes in late stage of breast cancer development. Importantly, seven genes were identified to have consistent changes in both early stage and late stage, indicating they might play "driving" roles in the breast cancer development. Of these 7 genes, 5 have been shown to be involved in breast cancer progression by previous studies, which demonstrates the validity of our analyses. Notably, DNAPTP3 was identified for the first time to play an oncogenic role in breast cancer development. In the GO term analyses, cell cycle genes was found to play more important roles in the early stage while biological adhesion was indicated to be more specifically involved in late stage of breast cancer development. SIGNIFICANCE: Our systematic analyses provide better understanding of the unique gene profiles and biological processes during the breast cancer development and identify more potentially important targets for future studies, such as DNAPTP3.
BACKGROUND:Ductal carcinoma in situ (DCIS) is a common type of non-invasive breast cancer and can sometimes progress into invasive breast cancer (IBC). Identification of the critical genes and biological processes specifically and/or commonly changed in DCIS or IBC can help us understand more about breast cancer development and provide more critical targets and signal transduction pathways for the diagnosis and treatments for breast cancerpatients. AIM AND METHODS: We aimed to gain more understanding about the whole process of IBC development, especially in the early stage. Here we systematically analyzed an online breast cancerpatient database to identify those significantly changed genes and biological processes in epithelium from normal stage to DCIS stage or from DCIS stage to IBC stage. RESULTS: 344 specific genes, such as FN1, AURKA and HSPA8, were found to be significantly changed (both upregulated and downregulated) in DCIS group in comparison with normal tissue group, which represents the gene profile changes in early stage of breast cancer development. Meanwhile, 304 specific genes were significantly changed (both upregulated and downregulated) in IBC group in comparison with normal tissue group, which represents the gene profile changes in late stage of breast cancer development. Importantly, seven genes were identified to have consistent changes in both early stage and late stage, indicating they might play "driving" roles in the breast cancer development. Of these 7 genes, 5 have been shown to be involved in breast cancer progression by previous studies, which demonstrates the validity of our analyses. Notably, DNAPTP3 was identified for the first time to play an oncogenic role in breast cancer development. In the GO term analyses, cell cycle genes was found to play more important roles in the early stage while biological adhesion was indicated to be more specifically involved in late stage of breast cancer development. SIGNIFICANCE: Our systematic analyses provide better understanding of the unique gene profiles and biological processes during the breast cancer development and identify more potentially important targets for future studies, such as DNAPTP3.
Authors: Jessica L S Zylla; Mariah M Hoffman; Simona Plesselova; Somshuvra Bhattacharya; Kristin Calar; Yohannes Afeworki; Pilar de la Puente; Etienne Z Gnimpieba; W Keith Miskimins; Shanta M Messerli Journal: Cancers (Basel) Date: 2022-03-30 Impact factor: 6.639